ClinicalTrials.gg
CompletedNCT03984994Updated Oct 29, 2025Results posted

Muscle Capillarization and Sarcopenia

An interventional study of Aerobic exercise training and Strength training in Sarcopenia, sponsored by Baltimore VA Medical Center. Completed at 2 sites in United States. Open to participants aged 65 Years to 88 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-29.

Sponsored by Baltimore VA Medical Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
65 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 187 studies in Sarcopenia with a site in United States — 36 open to participants now, 46 under way, 1 of them phase 3. Sarcopenia · United States.

Enrollment
126th of 146
14 · median 40
Started
2021
with 9 others
No phase
101 of 187
18 open now
Registered
111th of 187
by date

Among the 187 studies in Sarcopenia with a site in United States, this one is the 126th largest by enrollment of the 146 interventional ones that give a count, is one of 10 that started in 2021, is one of 101 with no phase, and was the 111th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

36 of the 187 studies in Sarcopenia with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 65 Years to 88 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Sarcopenia with a site in United States, or all of them as a file.
02

Study summary

Aging is associated with a loss of muscle mass, termed sarcopenia, that reduces mobility, decreases physical function and accelerates progression of other age-related disorders. This study is designed to determine whether increasing skeletal muscle capillarization through aerobic exercise will enhance muscular adaptations to strength training in older adults with sarcopenia.

Read the detailed description

Sarcopenia, or the aging-related loss of muscle mass, affects a large number of older adults. The presence of sarcopenia is associated with physical disability, poor quality of life, and all-cause mortality, in part because sarcopenic adults have low muscle skeletal muscle capillarization and may lack the adequate perfusion needed to maintain muscle mass and function. This study will test the effects of increasing skeletal muscle capillarization through aerobic exercise training on responses to resistance training in older adults. Eligible participants will be randomized to one of two groups, resistance training preceded by aerobic exercise training (AEX-RT), or resistance training followed by aerobic exercise training (RT-AEX). Participants in the AEX-RT group will undergo 3 months of aerobic exercise training to increase skeletal muscle capillarization, followed by 3 months of resistance training. Participants in the RT-AEX group will undergo 3 months of resistance training, followed by 3 months of aerobic exercise training. Before and after the interventions, participants will undergo assessments of muscle size, strength, and capillarization, as well as assessments of physical function.

03

Conditions studied

  • Sarcopenia

Keywords

  • muscle
  • capillary
  • exercise
04

Who can participate

Ages eligible
65 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • = 18-32.5 kg/m2
  • Non-smoker
  • Presence of at least moderate sarcopenia (low muscle mass per unit body height)

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of diabetes, cancer, pulmonary or renal disease
  • Physical impairment preventing exercise
  • Recent history of exercise training
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Aerobic exercise training followed by resistance training

    Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training

    Other: Aerobic exercise training · Other: Strength training

  • Active comparator
    Resistance training followed by aerobic exercise training

    Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training

    Other: Aerobic exercise training · Other: Strength training

Interventions

  • OtherAerobic exercise training

    3 months of center-based, supervised treadmill exercise

  • OtherStrength training

    3 months of center-based, supervise strength training

06

What researchers measure

Primary outcomes

  1. Skeletal Muscle Capillarization

    Change in the number of capillaries per unit of skeletal muscle tissue after resistance training. The aims of the study were to compare responses to resistance training between arms/groups. Therefore, only the resistance training-induced change (post minus pre-resistance training) is assessed and analyzed as this is the primary outcome for each arm.

    Time frame: 3 months (post minus pre-resistance training)

  2. Quadriceps Muscle Cross-sectional Area

    Change in the size of the thigh muscles. The aims of the study were to compare responses to resistance training between arms/groups. Therefore, only the resistance training-induced change (post minus pre-resistance training) is assessed and analyzed as this is the primary outcome for each arm.

    Time frame: 3 months (post minus pre-resistance training)

Secondary outcomes

  1. Skeletal Muscle Fiber Size

    Change in the cross-sectional size of individual thigh skeletal muscle fibers. The aims of the study were to compare responses to resistance training between arms/groups. Therefore, only the resistance training-induced change (post minus pre-resistance training) is assessed and analyzed as this is the primary outcome for each arm.

    Time frame: 3 months (post minus pre-resistance training)

  2. Muscle Strength

    Change in the strength/force produced by skeletal muscles of the thigh. Only the resistance training-induced change (post minus pre-resistance training) is reported as this is the primary outcome for each arm.

    Time frame: 3 months (post minus pre-resistance training)

07

Results

Posted Oct 29, 2025

Participant flow

Participant flow — Overall Study
MilestoneAerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise Training
Started77
Completed56
Not completed21
Withdrew: Withdrawal by subject21

Outcome measures

PrimarySkeletal Muscle Capillarization

Change in the number of capillaries per unit of skeletal muscle tissue after resistance training. The aims of the study were to compare responses to resistance training between arms/groups. Therefore, only the resistance training-induced change (post minus pre-resistance training) is assessed and analyzed as this is the primary outcome for each arm.

Time frame:
3 months (post minus pre-resistance training)
Reported as:
Mean · capillaries per muscle fiber
Skeletal Muscle Capillarization
capillaries per muscle fiberAerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise Training
Skeletal Muscle Capillarization0.4 ± 0.10.2 ± 0.1
Statistical analysis
  • Aerobic Exercise Training Followed by Resistance Training vs Resistance Training Followed by Aerobic Exercise Training · t-test, 2 sided · p = 0.27 · Mean difference (final values): 0.2
PrimaryQuadriceps Muscle Cross-sectional Area

Change in the size of the thigh muscles. The aims of the study were to compare responses to resistance training between arms/groups. Therefore, only the resistance training-induced change (post minus pre-resistance training) is assessed and analyzed as this is the primary outcome for each arm.

Time frame:
3 months (post minus pre-resistance training)
Reported as:
Mean · square centimeters
Quadriceps Muscle Cross-sectional Area
square centimetersAerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise Training
Quadriceps Muscle Cross-sectional Area2.5 ± 2.00.7 ± 2.6
Statistical analysis
  • Aerobic Exercise Training Followed by Resistance Training vs Resistance Training Followed by Aerobic Exercise Training · t-test, 2 sided · p = 0.22 · Mean difference (final values): 1.8
SecondarySkeletal Muscle Fiber Size

Change in the cross-sectional size of individual thigh skeletal muscle fibers. The aims of the study were to compare responses to resistance training between arms/groups. Therefore, only the resistance training-induced change (post minus pre-resistance training) is assessed and analyzed as this is the primary outcome for each arm.

Time frame:
3 months (post minus pre-resistance training)
Reported as:
Mean · square micrometers
Skeletal Muscle Fiber Size
square micrometersAerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise Training
Skeletal Muscle Fiber Size607 ± 108356 ± 227
Statistical analysis
  • Aerobic Exercise Training Followed by Resistance Training vs Resistance Training Followed by Aerobic Exercise Training · t-test, 2 sided · p = 0.21 · Mean difference (final values): 251
SecondaryMuscle Strength

Change in the strength/force produced by skeletal muscles of the thigh. Only the resistance training-induced change (post minus pre-resistance training) is reported as this is the primary outcome for each arm.

Time frame:
3 months (post minus pre-resistance training)
Reported as:
Mean · Newton-meters
Muscle Strength
Newton-metersAerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise Training
Muscle Strength12.7 ± 2.32.0 ± 5.8
Statistical analysis
  • Aerobic Exercise Training Followed by Resistance Training vs Resistance Training Followed by Aerobic Exercise Training · t-test, 2 sided · p = 0.28 · Mean difference (final values): 10.7

Adverse events

Collected over Data were collected over 6 months of study participation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aerobic Exercise Training Followed by Resistance Training0/7 (0%)0/7 (0%)0/7 (0%)
Resistance Training Followed by Aerobic Exercise Training0/7 (0%)0/7 (0%)0/7 (0%)

Baseline characteristics

All participants assigned to an intervention are included.

Age, Categorical
Age, Categorical(Participants)Aerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise TrainingTotal
<=18 years000
Between 18 and 65 years000
>=65 years7714
Age, Continuous
Age, Continuous(years)Aerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise TrainingTotal
Mean78 ± 473 ± 675 ± 6
Sex: Female, Male
Sex: Female, Male(Participants)Aerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise TrainingTotal
Female459
Male325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise TrainingTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American145
White628
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)Aerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise TrainingTotal
United States7714
Appendicular Lean Mass (kg)
Appendicular Lean Mass (kg)(kilograms)Aerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise TrainingTotal
Mean17.1 ± 1.919.3 ± 5.418.4 ± 4.4
Quadriceps muscle strength (Newton*meters)
Quadriceps muscle strength (Newton*meters)(Newton*meters)Aerobic Exercise Training Followed by Resistance TrainingResistance Training Followed by Aerobic Exercise TrainingTotal
Mean91 ± 15107 ± 30101 ± 25
08

Study locations

2 sites
  • University of Maryland, Baltimore & Baltimore VA Medical Center
    Baltimore, Maryland 21201, United States
  • University of Maryland
    College Park, Maryland 20742, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Apr 2024, 29 months.

Results were first posted in Oct 2025, 1 year 5 months after primary completion.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 29 months is above that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2019
First posted
Jun 13, 2019
StartActual
Nov 1, 2021
Primary completionActual
Apr 30, 2024
CompletionActual
Apr 30, 2024
Results first posted
Oct 29, 2025
Last update
Oct 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03984994
Lead sponsor
Baltimore VA Medical Center
Responsible party
Steven J. Prior, Ph.D. (Assistant Professor, University of Maryland, College Park) — Principal investigator
First posted
Jun 13, 2019
Start date
Nov 1, 2021
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Results posted
Oct 29, 2025
Last update
Oct 29, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion